cg0070,pembrolizumab
kissei,cg oncology,merck
['core1', 'keytruda', 'cg0070', 'thanks', 'cgoncology', 'cg oncology']
excited to share our updated data from our #core1 study with our #oncolytic #immunotherapy #cg0070 in combo with #keytruda at #asco22! 92%
patients at 3 months cr, 75% at 12 months! thanks for presenting these results. 
CG Oncology is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer